Rearming the body’s immune system to fight cancer
We’re developing more precise and more accessible treatment alternatives for patients with solid cancers
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.
Some of our partners
Latest news
Cartherics’ CEO discusses the future of solid tumour therapy
By Christine Filippis / February 15, 2024
Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the...
Read More
Ovarian cancer: Biotech company Cartherics to start human trials of new drug
By Christine Filippis / February 12, 2024
There’s an urgent need for new treatment options for ovarian cancer patients who are often diagnosed at advanced stages when...
Read More
Positive pre-IND meeting with US FDA for new ovarian cancer cell therapy
By Christine Filippis / February 1, 2024
Melbourne, Australia, 1 February 2024 – Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the...
Read More
